(VIANEWS) – VISTIN PHARMA (VISTN.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| VISTIN PHARMA (VISTN.OL) | kr22.60 | 7.95% | 19.84% |
| TUBIZE-FIN (TUB.BR) | €104.20 | 0.98% | 4.97% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. VISTIN PHARMA (VISTN.OL)
7.95% Forward Dividend Yield and 19.84% Return On Equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. Vistin Pharma ASA was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.27.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 17.8. Meaning, the purchaser of the share is investing kr17.8 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.84%.
Volume
Today’s last reported volume for VISTIN PHARMA is 14352 which is 52.16% below its average volume of 30002.
Moving Average
VISTIN PHARMA’s worth is below its 50-day moving average of kr22.94 and under its 200-day moving average of kr22.97.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jun 5, 2024, the estimated forward annual dividend rate is 1.75 and the estimated forward annual dividend yield is 7.95%.
Sales Growth
VISTIN PHARMA’s sales growth is 10.6% for the current quarter and 6.6% for the next.
More news about VISTIN PHARMA.
2. TUBIZE-FIN (TUB.BR)
0.98% Forward Dividend Yield and 4.97% Return On Equity
Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium. The company was incorporated in 1928 and is based in Brussels, Belgium.
Earnings Per Share
As for profitability, TUBIZE-FIN has a trailing twelve months EPS of €1.99.
PE Ratio
TUBIZE-FIN has a trailing twelve months price to earnings ratio of 52.36. Meaning, the purchaser of the share is investing €52.36 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.97%.
Moving Average
TUBIZE-FIN’s worth is way above its 50-day moving average of €94.17 and way above its 200-day moving average of €77.70.
Volatility
TUBIZE-FIN’s last week, last month’s, and last quarter’s current intraday variation average was 1.18%, 0.42%, and 1.20%.
TUBIZE-FIN’s highest amplitude of average volatility was 1.28% (last week), 1.10% (last month), and 1.20% (last quarter).
More news about TUBIZE-FIN.
